Just - Evotec Biologics

The biomanufacturing landscape is changing. Are you ready? Continuous manufacturing is gaining momentum, offering significant advantages over traditional Very Large-Scale (VLS) approaches. Don't get left behind. Read our blog to understand the six key drivers of this shift. Read now: https://hubs.ly/Q02Nn3TN0 To learn more about continuous manufacturing at Just – Evotec Biologics, visit: https://hubs.ly/Q02Nn38X0 or contact us via: Info@Evotec.com #Biomanufacturing #ContinuousManufacturing #Biopharma

Evotec and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets. To learn more, read the full press release here- https://hubs.ly/Q02NNq4Z0 #ResearchNeverStops #TogetherForMedicinesThatMatter

Once a feasibility study has shown that your fed-batch process would benefit from being converted to a #continuousbiomanufacturing platform, what are the next steps? Just - Evotec Biologics offers Commercial Process Development services that establish your product on a 25-day fully end-to-end continuous biomanufacturing platform and assess robustness. To learn more visit our website: https://hubs.ly/Q02Nz1cv0 Or contact us: info@evotec.com

It's time to revolutionize your drug development process. Join Evotec and Just - Evotec Biologics at CPhI Milan and discover how we're pushing the boundaries of what's possible. Explore our cutting-edge solutions: - API and drug product capabilities to accelerate your path to market - Innovative development and manufacturing services for antibody and antibody-related therapeutics - Integrated continuous manufacturing platforms for unparalleled efficiency and flexibility Curious to see it all in action? Schedule a meeting with our experts to discuss your specific needs, or book a site visit to our Verona facility and witness innovation firsthand. Find all the details you need here: https://hubs.ly/Q02Nk4M40 #CPHI #DrugDevelopment #Biologics

Understand the Sustainability Benefits of #ContinuousBiomanufacturing The NIIMBL Process Intensification Sustainability workstream is paving the way for sustainable, carbon-neutral bioprocessing of mAbs by 2030. By adopting intensified, continuous manufacturing with single-use technologies, they’re taking significant steps towards a greener future. As a first step, they have assessed the process mass intensity (PMI), energy usage, and CO2 equivalent emissions of both fed batch and continuous manufacturing formats. Download Poster- https://hubs.ly/Q02N8xxF0 To learn more about continuous manufacturing at Just – Evotec Biologics, visit-https://hubs.ly/Q02N8vB50 Contact Us: Info@Evotec.com

Interested in learning more about bottlenecks in the #biologics market? Welcome to our mini-series covering this topic. In this first article we discuss limitations in #biomanufacturing and look at key challenges and how they can be overcome. https://hubs.ly/Q02MRQfc0 #biotherapeutics #ResearchNeverStops

The Future of #Biologics Supply: Are We Ready? Very Large-Scale Tanks or #ContinuousBiomanufacturing? Which approach will ensure cost-effective and accessible biotherapeutics? "It's really about making sure these miracle drugs are cost-effective and we can get them to patients because patients deserve our help." Join Brian Kelley of Vir Biotechnology and Randal Bass of Just-Evotec Biologics as they explore the future of antibody production and how we can ensure life-saving treatments reach those who need them. Watch now: https://hubs.ly/Q02MVl910 Stay ahead of the curve. Contact us at info@evotec.com to learn more. #ContinuousManufacturing #Biologics #Biotherapeutics

A feasibility study is a short and inexpensive study to allow you to assess the benefits of converting your fed-batch process to a #continuousbiomanufacturing platform. Feasibility studies involve three main stages: 1. Assessing your existing cell line to see how suitable it is for manufacturing in a perfusion culture. 2. Bench-scale experiments that not only assess productivity but also look at product quality to ensure that it meets previously manufactured lots. 3. Costs of goods modelling with the BioSolve cost-modelling software to show you what the cost of goods are likely to be when we scale up to the large-scale continuous manufacturing platform. To learn more: Visit website: https://hubs.ly/Q02MRFPX0 Contact us: info@evotec.com

Amgen and other biopharma leaders are embracing continuous manufacturing. Why? It's transforming how they produce life-saving medicines. Dive into a real-world case study: A hybrid continuous manufacturing process achieved: - 80% reduction in process media and buffer usage - 15x more product per batch - 45x higher productivity ...all without increasing costs or needing more space! The key? Smartly repurposing existing facilities and optimizing production times. The Impact: Lower costs for antibody therapeutics mean wider access for patients in need. Read the full study and learn how you can leverage these groundbreaking innovations below! https://hubs.ly/Q02MTsK50 #BiotechInnovation #PharmaManufacturing #HealthcareRevolution

Read the August issue of our monthly newsletter for the latest updates and exciting developments in #continuousmanufacturing. Industry Round-Up: In a study published in the Journal of Pharmaceutical Sciences the authors discuss the advantages of decentralized manufacturing in small-scale production facilities. Read our key takeaways. News at Just - Evotec Biologics: Our new J.POD biologics manufacturing facility is set to open this September in Toulouse, France. Read the latest article discussing continuous biomanufacturing's arrival in Europe and our recent case study about how OncoResponse partnered with us to develop a continuous manufacturing process for their Phase I clinical trials. For full details, read our newsletter here- https://hubs.ly/Q02MSshb0